{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:29:10Z","timestamp":1788863350617,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jgisurgery.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Gastrointestinal Surgery"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s11605-016-3336-3","type":"journal-article","created":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T20:07:12Z","timestamp":1481832432000},"page":"425-433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?"],"prefix":"10.1016","volume":"21","author":[{"given":"Dexter Yak Seng","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas Li-Xun","family":"Syn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janelle Niam Sin","family":"Phua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas I. Peng","family":"Soh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng Ean","family":"Chee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min En","family":"Nga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Shabbir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy Bok Yan","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Peng","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s11605-016-3336-3_bb0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10120-011-0056-y","article-title":"First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer","volume":"15","author":"Iwasa","year":"2012","journal-title":"Gastric Cancer"},{"key":"10.1007\/s11605-016-3336-3_bb0015","doi-asserted-by":"crossref","unstructured":"Imazawa M, Kojima T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yasui H, Yamazaki K, Taku K. Efficacy of sequential methotrexate and 5-fluorouracil (MTX\/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination. Gastric Cancer.2009; 12:153\u2013157","DOI":"10.1007\/s10120-009-0517-8"},{"key":"10.1007\/s11605-016-3336-3_bb0020","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH and Yonemura Y: Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: Best palliation with a ray of hope for cure. Oncology 2000; 58: 96\u2013107","DOI":"10.1159\/000012086"},{"key":"10.1007\/s11605-016-3336-3_bb0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial","volume":"9","author":"Koizumi","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1007\/s11605-016-3336-3_bb0030","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1200\/JCO.1994.12.5.970","article-title":"Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer","volume":"12","author":"Sautner","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1007\/s11605-016-3336-3_bb0035","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.1995.13.12.2961","article-title":"Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study","volume":"13","author":"Francis","year":"1995","journal-title":"J Clin Oncol."},{"key":"10.1007\/s11605-016-3336-3_bb0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1007\/s11605-016-3336-3_bb0045","doi-asserted-by":"crossref","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24: 4991\u20134997","DOI":"10.1200\/JCO.2006.06.8429"},{"key":"10.1007\/s11605-016-3336-3_bb0050","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O","article-title":"Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study","volume":"88","author":"Sadeghi","year":"2000","journal-title":"Cancer."},{"key":"10.1007\/s11605-016-3336-3_bb0055","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO;2-V","article-title":"Peritoneal carcinomatosis in nongynecologic malignancies. A prospective study of prognostic factors","volume":"63","author":"Chu","year":"1989","journal-title":"Cancer"},{"key":"10.1007\/s11605-016-3336-3_bb0060","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/jjco\/hyh063","article-title":"Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial","volume":"34","author":"Yamao","year":"2004","journal-title":"Jpn J Clin Oncol."},{"key":"10.1007\/s11605-016-3336-3_bb0065","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/jjco\/hym131","article-title":"A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites","volume":"37","author":"Oh","year":"2007","journal-title":"Jpn J Clin Oncol."},{"key":"10.1007\/s11605-016-3336-3_bb0070","doi-asserted-by":"crossref","unstructured":"Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Goto M, Nasu J, Denda T, Hamamoto Y, Takashima A, Fukuda H, Ohtsu A; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin Oncol. 2013;43:972\u2013980","DOI":"10.1093\/jjco\/hyt114"},{"key":"10.1007\/s11605-016-3336-3_bb0075","doi-asserted-by":"crossref","unstructured":"Kitayama J, Ishigami H, Yamaguchi H, Yamashita H, Emoto S, Kaisaki S, Watanabe T. Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites. Ann Surg Oncol 2014;21: 539\u2013546","DOI":"10.1245\/s10434-013-3208-y"},{"key":"10.1007\/s11605-016-3336-3_bb0080","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.28204","article-title":"A phase 2 trial of intravenous and intraperitoneal Paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis","volume":"119","author":"Yamaguchi","year":"2013","journal-title":"Cancer"},{"key":"10.1007\/s11605-016-3336-3_bb0085","first-page":"S10","article-title":"S-1 plus intravenous and intraperitoneal Paclitaxel for gastric cancer with peritoneal metastasis","volume":"5","author":"Kitayama","year":"2012","journal-title":"Gastrointest Cancer Res"},{"key":"10.1007\/s11605-016-3336-3_bb0090","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/annonc\/mdp260","article-title":"Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis","volume":"21","author":"Ishigami","year":"2010","journal-title":"Ann Oncol."},{"key":"10.1007\/s11605-016-3336-3_bb0095","doi-asserted-by":"crossref","unstructured":"Ishigami H, Kaisaki S, Yamaguchi H, Yamashita H, Emoto S, Kitayama J. Phase I study of weekly intraperitoneal paclitaxel combined with S-1 and oxaliplatin for gastric cancer with peritoneal metastasis. J Clin Oncol 2012;30 suppl 4; abstr 146","DOI":"10.1200\/jco.2012.30.4_suppl.146"},{"key":"10.1007\/s11605-016-3336-3_bb0100","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ejca.2011.12.017","article-title":"A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer","volume":"48","author":"Kim","year":"2012","journal-title":"Eur J Cancer."},{"key":"10.1007\/s11605-016-3336-3_bb0105","unstructured":"Japanese Research Society for Gastric Cancer. Japanese classification of gastric carcinoma. First English Ed. Tokyo: Kanehara; 1995."},{"key":"10.1007\/s11605-016-3336-3_bb0110","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1007\/s11605-016-3336-3_bb0115","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"10.1007\/s11605-016-3336-3_bb0120","unstructured":"Imano M, Peng YF, Itoh T, Nishikawa M, Satou T, Yasuda A, Inoue K, Kato H, Shinkai M, Tsubaki M, Yasuda T, Imamoto H, Nishida S, Furukawa H, Takeyama Y, Okuno K, Shiozaki H. A preliminary study of single intraperitoneal administration of paclitaxel followed by sequential systemic chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal metastasis. Anticancer Res 2012 ; 32:4071\u20134076"},{"key":"10.1007\/s11605-016-3336-3_bb0125","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00280-013-2122-0","article-title":"Phase I\/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis","volume":"71","author":"Society for Study of Peritoneal Carcinomatosis in Gastric Cancer","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1007\/s11605-016-3336-3_bb0130","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3892\/ol.2014.2651","article-title":"DCF intraperitoneal and intravenous dual chemotherapy regimen for advanced gastric cancer: A feasibility study","volume":"9","author":"Feng","year":"2015","journal-title":"Oncol Lett."},{"key":"10.1007\/s11605-016-3336-3_bb0135","first-page":"4093","article-title":"Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol","volume":"48","author":"Rowinsky","year":"1988","journal-title":"Cancer Res"},{"key":"10.1007\/s11605-016-3336-3_bb0140","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1470-2045(03)01074-X","article-title":"Intraperitoneal antineoplastic drug delivery: rationale and results","volume":"4","author":"Markman","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1007\/s11605-016-3336-3_bb0145","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000333803","article-title":"Impact of intraperitoneal chemotherapy after gastrectomy with positive cytological findings in peritoneal washings","volume":"47","author":"Imano","year":"2011","journal-title":"Eur Surg Res"},{"key":"10.1007\/s11605-016-3336-3_bb0150","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/(SICI)1097-0142(19960101)77:1<14::AID-CNCR4>3.0.CO;2-N","article-title":"Paclitaxel-induced apoptosis in human gastric carcinoma cell lines","volume":"77","author":"Chang","year":"1996","journal-title":"Cancer"},{"key":"10.1007\/s11605-016-3336-3_bb0155","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1111\/j.1349-7006.2009.01265.x","article-title":"Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl phosphorylcholinecon-butyl methacrylate) for peritoneal dissemination of gastric cancer","volume":"100","author":"Soma","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1007\/s11605-016-3336-3_bb0160","doi-asserted-by":"crossref","unstructured":"Kamei T, Kitayama J, Yamaguchi H, Soma D, Emoto S, Konno T, Ishihara K, Ishigami H, Kaisaki S, Nagawa H. Spatial distribution of intraperitoneally administrated paclitaxel nanoparticles solubilized with poly (2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) in peritoneal metastatic nodules. Cancer Sci. 2011;102:200\u2013205.","DOI":"10.1111\/j.1349-7006.2010.01747.x"},{"key":"10.1007\/s11605-016-3336-3_bb0165","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1158\/1078-0432.CCR-06-1941","article-title":"Limited tissue penetration of taxanes: A mechanism for resistance in solid tumors","volume":"13","author":"Kyle","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1007\/s11605-016-3336-3_bb0170","doi-asserted-by":"crossref","unstructured":"Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirz\u00e9n F, Noh SH; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315\u2013321.","DOI":"10.1016\/S0140-6736(11)61873-4"},{"key":"10.1007\/s11605-016-3336-3_bb0175","doi-asserted-by":"crossref","unstructured":"Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imamoto H, Imano M, Kodera Y, Uenosono Y, Amagai K, Kadowaki S, Miwa H, Yamaguchi T, Yamaguchi H, Watanabe T, Kitayama J, Japan Intraperitoneal Chemotherapy Study Group (JIPG). Phase III study of intraperitoneal paclitaxel plus s-1\/paclitaxel compared with s-1\/cisplatin in gastric cancer patients with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol 2016; 34 (Suppl) abstr 4014","DOI":"10.1200\/JCO.2016.34.15_suppl.4014"},{"key":"10.1007\/s11605-016-3336-3_bb0180","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10120-015-0575-z","article-title":"Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification","volume":"19","author":"Yoshida","year":"2016","journal-title":"Gastric Cancer"}],"container-title":["Journal of Gastrointestinal Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11605-016-3336-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11605-016-3336-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X23026008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X23026008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11605-016-3336-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T19:51:11Z","timestamp":1761076271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1091255X23026008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S1091255X23026008"],"URL":"https:\/\/doi.org\/10.1007\/s11605-016-3336-3","relation":{},"ISSN":["1091-255X"],"issn-type":[{"value":"1091-255X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?","name":"articletitle","label":"Article Title"},{"value":"Journal of Gastrointestinal Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s11605-016-3336-3","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Society for Surgery of the Alimentary Tract. Published by ELSEVIER INC. All rights reserved. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}